Dermata Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| DERMATA THERAPEUTICS, INC. | |
| (Registrant) | |
| Date: March 26, 2026 | /s/ Gerald T. Proehl |
|---|---|
| Gerald T. Proehl | |
| Chief Executive Officer | |
| (Principal Executive Officer) | |
| Date: March 26, 2026 | /s/ Kyri K. Van Hoose |
| Kyri K. Van Hoose | |
| Chief Financial Officer | |
| (Principal Financial and Accounting Officer) |
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Gerald T. Proehl | President, Chief Executive Officer, Chairman (Principal Executive Officer) | March 26, 2026 |
| Gerald T. Proehl | ||
| /s/ Kyri K. Van Hoose | Chief Financial Officer (Principal Financial and Accounting Officer) | March 26, 2026 |
| Kyri K. Van Hoose | ||
| /s/ David Hale | Lead Director | March 26, 2026 |
| David Hale | ||
| /s/ Wendell Wierenga, Ph.D. | Director | March 26, 2026 |
| Wendell Wierenga, Ph.D. | ||
| /s/ Mary Fisher | Director | March 26, 2026 |
| Mary Fisher | ||
| /s/ Andrew Sandler, M.D. | Director | March 26, 2026 |
| Andrew Sandler, M.D. | ||
| /s/ Steven J. Mento, Ph.D. | Director | March 26, 2026 |
| Steven J. Mento, Ph.D. | ||
| /s/ Kathleen Scott | Director | March 26, 2026 |
| Kathleen Scott | ||
| /s/ Brittany Bradrick | Director | March 26, 2026 |
| Brittany Bradrick | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.